EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们继续与拜耳公司在血栓形成和止血领域进行合作研究。我们正在进行一项研究项目，以确定拜耳提供的PAR1拮抗剂是否具有治疗血栓栓塞性疾病的潜力。首先，5个化合物将在体外进行评估，1个化合物将在体内进行测试。随后，3个化合物将进行体外评价，2个化合物将进行体内评价。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We continue our collaborative research with Bayer Corp. in areas of in thrombosis and hemostasis. We are engaged in a research project to generate definitive information whether PAR1 antagonists provided by Bayer have therapeutic potential for treatment of thromboembolic diseases. First, 5 compounds will be evaluated ex vivo, and 1 compound will be tested in vivo. Subsequently, 3 compounds will be evaluated ex vivo, and two compounds will be evaluated in vivo.